Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center (NCT05095948)
Mapping the Processes of Cancer Care Delivery at a Comprehensive Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
This study examines how cancer care is delivered in oncology and supportive care clinics. Collecting patient feedback may help doctors better understand the processes of cancer care in oncology and supportive care clinics.
Who can join: Review the eligibility criteria below.
Location: M D Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
- Discussion (PROCEDURE)
- Electronic Health Record Review (OTHER)
- Questionnaire Administration (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- M D Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (713) 792-6258
Email: dhui@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Malignant Solid Neoplasm
- Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial — Birmingham, Alabama
- Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors — Houston, Texas
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors — Boston, Massachusetts
- Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression — Houston, Texas
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer — Phoenix, Arizona
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors — Sacramento, California
Explore by condition: All Metastatic Malignant Solid Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.